Loading patent…
AssigneeThe United States of America, as represented by the Secretary, Dept. of Health and Human Services
InventorsChristopher B. Buck, Diana V. Pastrana
Estimating the term…
Disclosed herein are methods of eliciting an immune response against a polyomavirus (for example, BKV serotype I (BKV-I), BKV serotype II (BKV-II), BKV serotype III (BKV-III) and/or BKV serotype IV (BKV-IV)) and methods of treating or inhibiting polyomavirus-associated pathology (such as polyomavirus-associated nephropathy, BKV-associated hemorrhagic cystitis, or JC virus-associated progressive multifocal leukoencephalopathy; PML). Further disclosed are immunogenic compositions of use in the disclosed methods. Also disclosed are methods of selecting an organ transplant donor and/or recipient including detecting whether the prospective donor and/or recipient has BKV serotype-specific (such as BKV serotype IV-specific) neutralizing antibodies.
A method of treating or inhibiting BK polyomavirus-associated nephropathy or BK polyomavirus-associated hemorrhagic cystitis in a subject, comprising administering to a subject in need of treatment for or inhibition of BK polyomavirus-associated nephropathy or BK polyomavirus-associated hemorrhagic cystitis a therapeutically effective amount of at least one isolated BKV serotype IV (BKV-IV) capsid polypeptide or a nucleic acid encoding the at least one BKV-IV capsid polypeptide, thereby treating or inhibiting the BK polyomavirus-associated nephropathy or the BK polyomavirus-associated hemorrhagic cystitis.
Dependencies are inferred from the claim text.